Evidence map›Paper›PMID 41484087›Full record

ArticleCell death & disease2026

Damage-induced pyroptosis drives endogenous thymic regeneration by activating the purinergic receptor P2Y2.

Sinéad Kinsella, Cindy A Evandy, Kirsten Cooper, Erin Kirsche, Makya Warren, Paul deRoos, Antonella Cardinale, Lorenzo Iovino, David Granadier, Colton W Smith and 4 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sinéad KinsellaDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Cindy A EvandyDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kirsten CooperDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Erin KirscheDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Makya WarrenDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Paul deRoosDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Antonella CardinaleDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenzo IovinoDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
David GranadierDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Colton W SmithDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3669-8327
Kayla HopwoDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Lucas B SullivanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6745-8222
Enrico VelardiDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-8383-0453
Jarrod A DudakovDivision of Translational Science and Therapeutics, Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA. jdudakov@fredhutch.org.ORCID http://orcid.org/0000-0001-6220-5632

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Thymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI Bonnie LaFleur · 2017 to 2026
$23.5M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
Promoting T cell reconstitution after hematopoietic cell transplantationR35HL171556 · NHLBI · FRED HUTCHINSON CANCER CENTER · PI Jarrod Dudakov · 2024 to 2026
$3.6M
Modulation of signaling from damage-associated molecular patterns to improve radiation-induced thymic dysfunctionU01AI170035 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Jarrod Dudakov · 2022 to 2026
$3.0M
Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplantR01HL145276 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUDAKOV, JARROD · 2019 to 2023
$2.8M
Regulation of thymic regeneration by GPR39R01HL165673 · NHLBI · FRED HUTCHINSON CANCER CENTER · PI DUDAKOV, JARROD · 2022 to 2023
$1.2M
American Society of Hematology (ASH) ASH ScholarNCI NIH HHS P30 CA015704NHLBI NIH HHS R01 HL145276NHLBI NIH HHS R01 HL165673NHLBI NIH HHS R35 HL171556NIAID NIH HHS U01 AI170035NIA NIH HHS P01 AG052359NIDDK NIH HHS U54 DK106829U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL145276U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL165673U.S. Department of Health & Human Services | National Institutes of Health (NIH) U01-AI70035
6 · The paper itself

Abstract

T cell recovery is critical following damage, such as hematopoietic cell transplantation (HCT), with increased reconstitution associated with improved clinical outcomes. Endogenous thymic regeneration, a crucial process for restoring immune competence following cytoreductive therapies such as HCT conditioning, is often delayed, limiting T cell reconstitution. Fully understanding the molecular mechanisms driving regeneration is therefore crucial for uncovering therapeutic targets that can be exploited to enhance thymic function. Here, we identified that CD4+ CD8+ thymocytes rapidly and acutely undergo lytic cell death, specifically pyroptosis, following acute damage caused by ionizing radiation, and release damage-associated molecular patterns (DAMPS) into the thymic microenvironment, including ATP. Extracellular ATP stimulates the P2Y2 purinergic receptor on thymic epithelial cells (TECs)-a stromal cell crucial for supporting T cell development-resulting in the upregulation FOXN1, the master TEC transcription factor. Targeting the P2Y2 receptor with a P2Y2 agonist, UTPγS, promotes rapid regeneration of the TEC compartment in vivo following acute damage. These findings reveal a novel damage-sensing mechanism employed by the thymus where thymocytes adopt an alternative cell death mechanism which promotes thymic repair via P2Y2 signaling in TECs. This work identifies P2Y2 as a promising therapeutic target for enhancing thymus regeneration and improving immune recovery after HCT.

Indexed as

PyroptosisReceptors, Purinergic P2Y2RegenerationThymus GlandAdenosine TriphosphateAnimalsEpithelial CellsMiceMice, Inbred C57BLThymocytesAdenosine TriphosphateReceptors, Purinergic P2Y2

Identifiers

PMID41484087
PMCPMC12859001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.